FILING ANALYSIS · MONDAY, NOVEMBER 16

Astrazeneca AZN — RNS: Klygefa Gefurulimab Approved In The Us

positive

Astrazeneca's Klygefa (gefurulimab) has received FDA approval for adult anti-AChR+ generalized myasthenia gravis, a significant regulatory milestone for the company.

The filing

Astrazeneca — Klygefa Gefurulimab Approved In The Us

Read the RNS announcement →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+